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Multimodal approaches are nowadays successfully applied in cancer therapy. Primary
locally acting therapies such as radiotherapy (RT) and surgery are combined with systemic
administration of chemotherapeutics. Nevertheless, the therapy of cancer is still a
big challenge in medicine. The treatments often fail to induce long-lasting anti-tumor
responses. Tumor recurrences and metastases result. Immunotherapies are therefore
ideal adjuncts to standard tumor therapies since they aim to activate the patient’s immune
system against malignant cells even outside the primary treatment areas (abscopal
effects). Especially cancer vaccines may have the potential both to train the immune
system against cancer cells and to generate an immunological memory, resulting in
long-lasting anti-tumor effects. However, despite promising results in phase I and II
studies, most of the concepts finally failed. There are some critical aspects in development
and application of cancer vaccines that may decide on their efficiency. The time point
and frequency of medication, usage of an adequate immune adjuvant, the vaccine’s
immunogenic potential, and the tumor burden of the patient are crucial. Whole tumor
cell vaccines have advantages compared to peptide-based ones since a variety of tumor
antigens (TAs) are present. The master requirements of cell-based, therapeutic tumor
vaccines are the complete inactivation of the tumor cells and the increase of their
immunogenicity. Since the latter is highly connected with the cell death modality, the
inactivation procedure of the tumor cell material may significantly influence the vaccine’s
efficiency. We therefore also introduce high hydrostatic pressure (HHP) as an innovative
inactivation technology for tumor cell-based vaccines and outline that HHP efficiently
inactivates tumor cells by enhancing their immunogenicity. Finally studies are presented
proving that anti-tumor immune responses can be triggered by combining RT with
selected immune therapies.
Keywords: immunotherapy, vaccination, cancer therapy, multimodal, anti-tumor immunity, whole cell-based
vaccines, high hydrostatic pressure, radiotherapy
IMMUNOTHERAPY IN CANCER TREATMENT
Today’s cornerstones in cancer therapy are radiotherapy (RT),
chemotherapy (CT), and surgery. Local tumor control and/or
complete regression are achievable for many tumor entities,
since these methods alone and especially combinations of them
have been further improved. Nevertheless, development of tumor
recurrence and metastases substantially deteriorates the patient’s
prognosis. To win the fight against cancer is therefore not only
restricted to kill all tumor cells of the primary tumor, but also
to act on the patient’s whole body to achieve a long-lasting anti-
tumor effect which keeps remaining and recurrent tumor cells in
check. Therefore, systemic approaches are required that activate
the patient’s immune system against the tumor. The cells of the
immune system have to be trained to control residual disease and
hidden metastases (Sistigu et al., 2011).
Cancer immunotherapies (CI) aim to be, beneath their role in
primary local tumor killing, the second line therapy against recur-
rent tumors and metastases by priming the patient’s immune
system to elicit an anti-tumor response (Sharma et al., 2011).
First and foremost, the combination of standard therapies with
immunotherapeutic strategies is auspicious to reach stable disease
and to improve overall survival. Additionally, due to a lower toxic-
ity compared with chemotherapeutic agents, immunotherapeutic
approaches are more compliant for normal tissue and the whole
organism. Especially combinations of RT and CI are promising
since they are capable to elicit anti-tumor effects outside the radi-
ation field, a phenomenon called abscopal effect (Demaria et al.,
2004; Frey et al., 2012). RT with ionizing irradiation (X-ray)
triggers the release of pro-inflammatory signals. It further indi-
rectly contributes to the activation of dendritic cells (DCs) by
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generating modified and new tumor specific antigens and by
inducing the release of danger signals of irradiated tumor cells.
Further, an enhanced loading of DCs with tumor antigens (TAs)
of irradiated tumor cells has been observed (Teitz-Tennenbaum
et al., 2008). Therefore, combination of RT with DC-based CI is
considered to be ideal for the induction of tumor specific immune
responses.
The field of immunotherapy offers a broad array of approaches
including monoclonal tumor specific antibodies that have been
already established in clinical treatment of several tumor enti-
ties (Scott et al., 2012), the application of immune activating
cytokines (Dranoff, 2004), or even gene transfer of adoptive T-cell
receptor (TCR) to obtain large numbers of tumor-reactive T cells.
The in vivo stimulation of an anti-tumor response by vaccines is
another important approach. Especially whole tumor cell-based
vaccines offer a wide array of TAs. Contrary to peptide-based
vaccines, defining andmanufacturing of individual and immuno-
genic antigens is not required since whole cells comprise all
immunologically relevant tumor peptides (Figure 1). Of special
note is that this multiplicity decreases the risk of tumor escape.
Crucial in generating effective whole tumor cell vaccines is to
induce, or even increase their immunogenicity (Frey et al., 2008).
Since the way cells die is closely connected to their immunogenic
potential, the inactivation process of tumor cells is often the deter-
mining factor for a vaccine’s potency (Tesniere et al., 2008a,b).
Currently, we investigate high hydrostatic pressure (HHP, mean-
ing pressure stages >100MPa) treatment as a novel inactivation
FIGURE 1 | Challenges and changes of whole tumor cell-based
vaccines. As compared to peptide-based vaccines, a high variety of
relevant tumor antigens is provided by whole tumor cell-based vaccines.
Therefore, the tumor antigens have not to be individually defined. However,
there are some crucial challenges that may decide about the vaccine’s
efficiency and productivity including the immunogenic potential of tumor
cell material and a reliable manufacturing process associated with a high
reproducibility. Furthermore, the limited availability of tumor cell material
has to be taken into account. Nevertheless, when these resolvable
problems have been resolved, whole tumor cell-based vaccines will be
prime immune therapies for personalized tumor treatments.
technology of whole tumor cells. We already proved that var-
ious tumor cell lines can be efficiently inactivated by treating
them with pressure ≥200MPa and observed in preclinical mouse
models that that HHP-killed tumor cells are immunogenic (Weiss
et al., 2010b).
IMMUNE THERAPIES WITH CYTOKINES ANDMONOCLONAL
ANTIBODIES
Before we go into detail how whole tumor cell vaccines induce
anti-tumor immunity, we will shortly introduce further strategies
of CI with “agents” that do not bear tumor peptides and antigens
such as cytokines or monoclonal antibodies.
Cytokines in the tumor microenvironment have a strong
influence on the host’s immunity. They may foster or suppress
tumor growth (Chometon and Jendrossek, 2009; Apte, 2010).
Consequently, the administration of distinct cytokines in can-
cer therapy can modulate the microenvironment of a tumor in a
way that leads to a better therapeutic outcome (Dranoff, 2004).
However, their administration can also induce relevant side
effects related with a moderate effectiveness (Kelley et al., 2003;
Dantzer and Kelley, 2007). Hence, combination of cytokines
with other strategies allows dose reduction. Clinically successful
phase III trials have been carried out with systemic administra-
tion of interleukin (IL)-2, that enhances natural killer (NK)-cell
and T-cell activity (Rosenberg et al., 1993; Fyfe et al., 1995),
or stimulators for TA presentation like granulocyte-macrophage
colony-stimulating factor (GM-CSF) (Dranoff et al., 1993), inter-
feron (IFN)-α (Biron, 2001), or IFN-γ (Bach et al., 1997). Since
immunity against cancer is a multi-step-process, the sole applica-
tion of cytokines is insufficiently. The role of cytokines in cancer
therapy and pathogenesis has been extensively discussed during
the last years (Dranoff, 2004; Margolin, 2008; Mellman et al.,
2011).
Beyond, immunity against malignant cells can be established
with monoclonal antibodies that trigger tumor cell apoptosis by
inducing antibody-dependent cellular or complement-mediated
cytotoxicity. Further, those antibodies may block growth factor
receptors or foster anti-tumor immune responses (reviewed in
King et al., 2008; Scott et al., 2012; Weiner et al., 2012).
Rituximab, an antibody that targets CD20 on B-cells and
causes B-cell apoptosis in B-cell lymphoma (Pescovitz, 2006), is
one of the prominent examples for the application of monoclonal
antibodies in CI. Others are antibodies such as Trastuzumab
(Hudis, 2007; Valabrega et al., 2007), acting against human epi-
dermal growth factor receptor 2 (HER-2) on cancer cells, or
Cetuximab, that acts against the epidermal growth factor recep-
tor (EGFR) (Cunningham et al., 2004; Bonner et al., 2006).
Bevacizumab is directed against vascular endothelial growth fac-
tor (VEGF) and the anti-cytotoxic T-lymphocytes (CTL) A-4
antibody Ipilimumab abrogates the inhibitory effects of CTLA-
4 on T-cell activation (Greenwald et al., 2001; Ferrara et al., 2004;
Scott et al., 2012). Via binding to Fc gamma receptors (FcγR) on
DCs,monoclonal antibodies contribute further to an induction of
adaptive anti-tumor immune responses. An antibody-mediated
enhanced cross-presentation of TAs was observed (Dhodapkar
et al., 2002, 2005; Weiner et al., 2010). Similar to chemothera-
peutics, monoclonal antibodies act directly in the whole tumor
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mass, but are more compliant for the patient, due to their low
toxicity. However, monoclonal antibodies have a narrow tar-
get antigen range. Nevertheless, a plenty of studies have been
performed using such antibodies. Scott and colleagues recently
summarized the advantages and disadvantages of this therapeutic
option against cancer (Scott et al., 2012).
Besides the above mentioned mechanisms, the potential of
antibodies and cytokines to activate the immune system accom-
panied with an establishment of immunological memory is still
low. A combination of CI strategies might be beneficial to induce
anti-tumor immunity and reduce the tumor cell growth and
induce tumor cell death, respectively (Van Elsas et al., 1999;
Takaku et al., 2010; Weiss et al., 2010a).
IMMUNOLOGICAL BASICS OF THE MODE OF ACTION OF
TUMOR VACCINES
Contrary to monoclonal antibodies, tumor vaccine strategies aim
to actively train the immune system going along with the devel-
opment of a long-lasting immunological memory. Hence, partic-
ularly the appearance of metastases and tumor recurrences can
potentially be counteracted or even avoided. Both, the innate and
the adaptive arm of the cellular immune system can contribute to
an effective attack toward tumor cells.
Lymphokine-activated killer (LAK) cells, NK cells, and
macrophages are crucial players of innate immunity, acting with
a low specificity but widespread against tumor cells with dif-
ferent histological background (Grimm et al., 1982; Rosenberg
et al., 1985; Krause et al., 2002; Terme et al., 2008). Cells of
the adaptive immune system, comprising CD4+ and CD8+ T-
lymphocytes, are more suitable to elicit a long-lasting immune
response, since they can specifically target TAs and differentiate
to memory cells. The three most important processes leading to
long-lasting tumor immunity were recently proposed byMellman
et al. (2011). In the first step, DCs must sample relevant TAs.
Secondly, DCs have to mature and to initiate the T-cell response.
Last but not least, the T-cells have to overcome the immunosup-
pression of the solid tumor and enter the tumor bed (Mellman
et al., 2011).
Tumor vaccinations offer a variety of strategies to activate and
train the immune system. Vaccination with distinct TAs, or whole
tumor cells have been performed to activate DCs in vivo. Further,
strategies with pulsing of DCs ex vivo with TAs are followed up.
Nevertheless, the generation of an effective, specific, and long-
lasting response against tumor cells is more challenging compared
to that against pathogens, since the tumor had repeatedly escaped
an immune surveillance (Novellino et al., 2005).
Transformed cells have several strategies to circumvent
immune activation (reviewed in Dunn et al., 2002; Igney and
Krammer, 2002). For example, presentation of TA on the tumor
cells’ surface is generally poor. This is evenmore present in metas-
tases that are often characterized by frequent mutations; this
helps transformed cells to escape from an initially induced spe-
cific response (Kim et al., 1975; Bailly et al., 1993). Moreover,
presentation and protein loading of major histocompatibility
complex (MHC)-class I molecules is often reduced or malfunc-
tioned avoiding lysis by cytotoxic T cells (Hicklin et al., 1999).
Further mechanisms in the microenvironment contribute to
tumor escape, such as the secretion of immunosuppressive fac-
tors including TGF-β (Li et al., 2006), IL-10 (Wittke et al., 1999),
or prostaglandin (Botti et al., 1998). These cytokines secreted by
tumor cells favor an immune deviation, characterized by a shift
toward a more Th2-polarized response that suppresses the estab-
lishment of an adaptive cellular response involving effector CD8+
T-lymphocytes (Maeda and Shiraishi, 1996; Shurin et al., 1999;
Ribas et al., 2000). The cytokine profile, a low stimulation by TA
and the missing stimulative conditions can finally lead to T-cell
anergy, to the induction of regulatory T-cells, and also to T-cell-
depletion (Staveley-O’Carroll et al., 1998; Zou, 2006). The major
challenges of an effective cancer vaccine are therefore to overcome
these immune suppressing mechanisms and to train the immune
system to recognize and to attack tumor cells.
For the induction of an effective and long-lasting anti-tumor
response, priming of CTL is crucial. CTLs are able to specifically
target TAs and to destroy tumor cells directly. Moreover, they may
differentiate into memory T-cells, which enable the development
of a prolonged anti-tumor response (Podack, 1995; Shresta et al.,
1998). For activation, T-cells have to meet their specific TA and
additionally have to receive co-stimulatory signals. Recognition
of TA is mediated by TCRs on naïve T-lymphocytes and antigen-
MHC complexes on antigen presenting cells (APCs). The binding
of the TA is restricted to MHC-class I or MHC-class II molecules
on CD8+ and CD4+ T-cells, respectively. Furthermore, APCs
provide co-stimulatory signals, including B7.1/B7.2 molecules
that interact with CD28 on T-cells, or CD40 receptors on T-cells
interacting with CD40 ligand (CD40 L). Without those additional
signals T-cells are not able to proliferate and to produce cytokines;
they even undergo apoptosis (Frauwirth and Thompson, 2002).
Contrary to the activation of CD4+ T-cells, the priming of CTLs
from naïve CD8+ T-cells is more complex and involves the inter-
play of DCs, T helper cells type 1 (Th1 cells), and cytokines
(Mellman et al., 2011).
Immature DCs constantly migrate through tissues and blood,
scanning their environment for potential pathogens or danger
signals. DCs recognize invading pathogens with their pathogen-
associated molecular patterns (PAMPs) recognition receptors
(PRRs). But DCs are not only activated by pathogen-derived
signals. According to the danger theory of Polly Matzinger
(Matzinger, 1994), the immune system is able to distinguish
between danger and non-danger. Dying mammalian cells release
danger-associated molecular patterns (DAMPs) that act as
potent stimuli for DCs. In the last years several DAMPs have
been described, including high mobility group box 1 protein
(HMGB-1), heat shock proteins (HSPs), and uric acid (Shi
et al., 2003; Bianchi, 2007). After the recognition by DCs,
the tumor cell is engulfed and antigen processing takes place.
Maturation of DCs has been initiated and is accompanied by
a decreasing potential of antigen assimilation combined with
increased migration ability. Consecutively, DCs migrate to the
lymph node (LN), where their peptide/MHC-class II com-
plex is presented to the antigen specific TCR on naïve CD4+
T-cell. DCs have to reach a fully mature stage to power an
effective immune response, because semi-mature DCs have
rather tolerogenic features (Rutella et al., 2006; Mellman et al.,
2011).
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The fate of T helper cell subtypes and therefore the type of
immune response are strongly determined by polarizing factors
that are secreted by DCs (O’Garra and Arai, 2000). The cytokines
IL-2, IL-12, and IFN-γ favor the differentiation of naïve CD4+
T-cells to T helper cell type 1 (Th1), while IL-10, IL-4, and IL-5
polarize a T helper cells type 2 (Th2) response (O’Garra and Arai,
2000). In regard to a CTL-mediated tumor response, the induc-
tion of a Th1 response is crucial since the interaction of Th1
cell with DCs renders the DCs themselves capable for the acti-
vation of naïve CD-8+ T-cells by CD40 and CD40-L interaction
(Schoenberger et al., 1998). Consequently, the primary contact
between tumor cells and DCs is pivotal for both the initialization
and the polarization of adaptive immune responses.
The cytokine milieu may also favor several other T helper sub-
classes besides Th1 and Th2 cells. For example, the development
of Th17 cells that secrete the cytokine IL-17 is promoted by TGF-
β and IL-6. The role of Th17 cells in tumor progression and/or
regression is under current investigation (Langowski et al., 2006;
Hirota et al., 2012; Liu et al., 2012; Middleton et al., 2012). In
conclusion, the course of adaptive immunity against cancer cells
is already initialized by innate immune cells, in particular by DCs.
The priming of DCs by malignant cells is mainly determined by
microenvironmental factors of the “meeting point” (Kapsenberg,
2003; De Jong et al., 2005).
Since danger signals released by dead tumor cells dictate the
DC’s behavior, they are crucial for the induction of anti-tumor
immune responses. Toll like receptors (TLR) on the DCs’ sur-
face can recognize both PAMPs and DAMPs and have a great
impact on anti-tumor immunity (Tesniere et al., 2008a). It has
been reported that ligation of TLR-4 and TLR-5 instructs DCs to
stimulate naïve T helper cells to a Th1 polarization while binding
of TLR-2 dictates a Th2 response (Agrawal et al., 2003). DAMPs
that are released by dying and dead cells can bind to TLRs and
are therefore capable to determine priming of DCs. For exam-
ple, HMGB-1 favors binding to TLR-4, while HSP-70 can interact
with TLR-2 and TLR-4 (Apetoh et al., 2007; Asea, 2008). Hence,
the form of tumor cell death, induced either in vivo by direct
cytotoxic therapy or ex vivo for vaccination purpose, strongly
determines whether an anti-tumor immune response is elicited
or not (Tesniere et al., 2008a). Inactivation technologies for the
preparation of whole tumor cell vaccines should therefore aim to
induce immunogenic tumor cell death forms.
CELL DEATH FORMS AN IMMUNOLOGICAL RELEVANCE
Today a variety of different cell death forms is described for mam-
malian cells. Some cell death forms are highly genetically deter-
mined; others display more accidental characteristics (Griffith
and Ferguson, 2011). Most attention was given to the two main
cell death forms, namely apoptosis and necrosis, since their
immune modulatory potential helped to understand how chronic
autoimmune diseases might develop and/or sustained (Gaipl
et al., 2006; Gaipl, 2009). Usually, apoptotic cells are immunolog-
ically silent or even tolerogenic. They are part of a physiological
process to maintain homeostasis of every multicellular organ-
ism. Apoptosis is characterized by several cell morphological
and biochemical features like DNA fragmentation, cell blebbing,
and condensation of the chromatin (Kerr et al., 1972; Griffith
and Ferguson, 2011). The silent clearance of apoptotic cells is
mediated by “find-me” signals that are released by apoptotic cells
to promote the attraction of phagocytes (Lauber et al., 2004;
Ravichandran and Lorenz, 2007). The latter recognize “eat me”
signals on the apoptotic cells’ surface, leading under healthy con-
ditions to a swift clearance of the dying cells. Engulfment of apop-
totic cells provokes in activated phagocytes even the secretion of
anti-inflammatory signals such as IL-10 and TGF-β (Voll et al.,
1997). However, it has recently turned out that under certain
circumstances apoptosis may also exhibit immune-stimulatory
features, in particular when treated with certain chemotherapeu-
tics (anthracyclines) or γ-irradiation (Casares et al., 2005; Obeid
et al., 2007; Tesniere et al., 2008a; Locher et al., 2010). The associ-
ated molecular mechanisms are not yet fully investigated, anyhow
there is evidence that the early exposition of the ER resident chap-
erone calreticulin together with ERP57 on the cell surface is one
key part of it (Obeid, 2008; Ma et al., 2011).
Contrary to the predominantly immunologically silent man-
ner of apoptotic cells, necrosis is associated with (pro-) inflam-
mation; hence it’s conditioned by a pathological process (Golstein
and Kroemer, 2007). The loss of membrane integrity results
in the secretion of danger signals that may lead to the activa-
tion and maturation of immune cells and generally generates
inflammatory conditions. Extracellular HSPs (Asea, 2008; Schmid
and Multhoff, 2012) and HMGB-1 are prominent examples for
such released immune activator proteins (Apetoh et al., 2007;
Bianchi, 2009; Schildkopf et al., 2011). Interestingly, some dan-
ger signals can be released by necrotic as well as apoptotic cells.
One has to consider that in the case of apoptosis the danger
signals are often modified before their release resulting in a con-
trary immunological outcome (Griffith and Ferguson, 2011). For
example, HMGB-1 is usually oxidized by reactive oxygen species
during the apoptotic process and thereby loses its immunologi-
cal potency (Urbonaviciute et al., 2009). This highlights that the
dying cell itself and its microenvironment determines whether
immune activation or immune suppression is triggered. The dif-
ferent forms of cell death are manifold and sometimes hard to
differentiate. Garg and colleagues recently summarized what fac-
tors determine the immunogenicity of the dying cells (Garg et al.,
2010). Even a programmed form of necrosis, the so called necrop-
tosis, has been described and the immunological consequences
of this cell death modality are currently under investigation
(Galluzzi et al., 2012).
If whole tumor cell vaccines are prepared by inactivation of
tumor cells, the immunogenicity of the dead cells should be
enhanced or at least maintained by this procedure. A main focus
of future cancer therapy concepts should be set on combina-
tion of classical anti-cancer therapies with immunotherapy in
order to accomplish the anti-tumor effects of both concepts.
Standard therapies such as RT or the treatment with particu-
lar chemotherapeutics should induce highly immunogenic dead
cells which generate an immune activating microenvironment
(Ma et al., 2011). Solely immunotherapeutic agents are not suf-
ficient to efficiently shift a strong anti-inflammatory tumor
microenvironment to an inflammatory one. Therefore, the tumor
cell death form of the whole tumor cells used as vaccine as well
as the cell death induced in the primary tumor by standard
Frontiers in Oncology | Molecular and Cellular Oncology October 2012 | Volume 2 | Article 132 | 4
Weiss et al. Vaccination in multimodal anti-tumor therapy
therapies are of great importance to trigger an effective anti-
tumor immunity.
AUTOLOGOUS AND ALLOGENEIC WHOLE TUMOR
CELL-BASED VACCINES IN THE CLINIC
During the last years, several vaccination strategies were evalu-
ated in pre-clinical and clinical phase I and II studies. However,
most of the tested vaccination approaches finally failed to achieve
clinical success in randomized phase III trials (summarized in
Rosenberg et al., 2004; Itoh et al., 2009; Klebanoff et al., 2011).
Table 1 summarizes the phase III trials containing whole tumor
cell-based vaccines. In 2010, an autologous DC-based vaccine
(Sipuleucel-T), used in prostate cancer, achieved FDA approval
in the USA (Cheever and Higano, 2011) and has led to a boost in
the development of new vaccination strategies and agents. For an
improvement of vaccine concepts, the big challenge for research
is to figure out the reasons for previous clinical failings of the
vaccines.
Most of the clinical studies reviewed by Rosenberg and
Klebanoff applied strategies based on vaccination with a single
peptide or protein. These vaccines have the disadvantage to be
restricted to a single target or, in the case of proteins, to few epi-
topes. Identification of TAs and proof of their immunogenicity
are challenging aspects. Difficulties may result from poor anti-
gen presentation on tumor cells or the appearance of frequent
mutations in metastases: Both may result in the loss of peptide-
specific effector T-cells’ ability to recognize the tumor cells.
Additionally, the efficiency of peptide-based vaccines is mostly
HLA-restricted, resulting in a constricted quantity of potentially
responding individuals (Chiang et al., 2010). Whole tumor cell
vaccines are promising to bypass complex procedures in defin-
ing individual antigens. The tumor cell surface comprises a huge
amount of potentially relevant antigens. Besides, the provided
antigen plurality impedes tumor escape. For an enhanced anti-
tumor response the additional application of immune adjuvants
such as Bacillus Calmette-Guérin (BCG) or cytokines is benefi-
cial. Ex vivo genetic manipulations of inactivated cell material are
also followed up, resulting in the secretion of GM-CSF (Simons
and Sacks, 2006), other cytokines, chemokines, or in increased
expression of MHC antigens (Pardoll, 1995).
Autologous tumor cell-derived material has already been
demonstrated in clinical studies to be a promising cancer vac-
cine. An adjuvant renal tumor cell lysate-based vaccine (Reniale®)
was applied in a phase III study for patients with renal-cell car-
cinoma after nephrectomy. The 5-year progression-free survival
rate improved to 77.4% compared to 67.8% in the control arm
(Jocham et al., 2004). In another study, a ten-year survival analy-
sis was performed for renal carcinoma patients also treated with
that autologous tumor lysate vaccine in an adjuvant setting. An
overall survival benefit (OS rates of 68.9% in the study group
versus 62.1% in the control group) was observed. Especially the
subgroup of patients with pT3 stage tumors did profit from this
adjuvant vaccination (OS rates of 53.6% in the study group ver-
sus 36.2% in the control group) (May et al., 2010). For those
vaccinations, necrotic cell lysates were obtained by freeze/thaw
cycles of whole tumor cells. These lysates consist of cell fragments
Table 1 | Overview of whole tumor cell-based vaccines that have been tested in Phase III trials.
Trade name Type of vaccine Cancer type Phase Included Observation Reference
patients periode
Sipuleucel-T Autologous dendritic
cell-based vaccine incubated
with PAP-GM-CSF fusion
protein
Prostate cancer III 512 3 years Cheever and Higano, 2011
Reniale Cell-lysate-based autologous
vaccine by freeze/thaw
cycles
Renal-cell carcinoma III 379 5 years Jocham et al., 2004
Reniale Cell-lysate-based autologous
vaccine by freeze/thaw
cycles
Renal-cell carcinoma III 692 10 years May et al., 2010
Oncovax Irradiated autologous tumor
cell-based vaccine with BCG
Colorectal cancer III 317 5 years Simons and Sacks, 2006
Prostate-GVAX Allogenic cell-based,
GM-CSF gene transduced
vaccine
Prostate cancer III 408 Prematurely
terminated
Higano et al., 2009
Prostate-GVAX Allogenic cell-based,
GM-CSF gene transduced
vaccine
Prostate cancer III 626 Prematurely
terminated
Small et al., 2009
Canvaxin Irradiated allogenic cell
mix-based vaccine with BCG
Melanoma III Stage III: 1100 Prematurely
terminated
Finke et al., 2007
Canvaxin Irradiated allogenic cell
mix-based vaccine with BCG
Melanoma III Stage IV: 670 Prematurely
terminated
Finke et al., 2007
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including parts of cellular membrane, RNA, and DNA as well
as cell organelles. Since the cell membrane is disturbed, danger
signals such as HSPs and HMGB-1 are released and may in vivo
stimulate the maturation of DCs (Sauter et al., 2000; Somersan
et al., 2001). Until today no generalized vaccination recommen-
dations for patients with renal cancer are given since further
controlled trials are recommended and necessary. Furthermore, it
has become obvious, that subgroups of patients exist that might
benefit most from such vaccinations (May et al., 2010).
For colorectal cancer, a vaccine consisting of irradiated whole
autologous tumor cells (Oncovax®) has been evaluated in clin-
ical studies (up to phase III) (Hanna Jr et al., 2001; Simons
and Sacks, 2006). For immunotherapy of melanoma, a quite
similar approach was tested. Patients diagnosed with metastatic
melanoma stage III/IV (n = 81) were included. After resection,
melanoma cell material was irradiated and re-injected together
with BCG. A survival benefit of the patients who received the vac-
cine was observed but it was only restricted to patients without
evidence of macroscopic disease during the vaccination period
(Baars et al., 2000). The delayed type hypersensitivity response
(DTH) correlated with the survival data of the patients.
These clinical trials illustrate that despite disappointing clini-
cal results of cancer vaccines (Klebanoff et al., 2011) also positive
ones exist. However, the clinical studies with whole tumor cell
vaccines curtailed the high expectations that were put into them.
Nevertheless, whole tumor cell-based vaccines have to be brought
back to bench and then again back to bedside, because highly
immunogenic autologous tumor cell-based vaccines may offer
great changes to cure cancer, especially when used in an adjuvant
setting to avoid tumor recurrences or metastases.
Besides autologous tumor cells, allogeneic ones might also be
used as cancer vaccines. Autologous tumor cells have the advan-
tage to provide the complete set of personalized TAs; including
individual mutated ones (Fournier and Schirrmacher, 2009).
Anyhow, relevant drawbacks exist with regard to the produc-
tion of autologous cell vaccines. Resectable tumors are needed
to obtain enough tumor material. The number of tumor cells
obtained after resection is often limited, especially in the case of
metastases or early stage tumors. To obtain an adequate tumor
cell amount, in vitro cultivation and expansion is often required
entailing other difficulties (e.g., maintenance of cell integrity, pro-
longed process duration) that may influence the immunogenicity
of the vaccine (Copier et al., 2007).
GVAX technology is one example for vaccine development
where genetically modified tumor cells were used for vaccination.
Granulocyte macrophage colony-stimulating factor (GM-CSF) is
transduced into the tumor cells since it has proven immune stim-
ulatory properties. It promotes recruitment and maturation of
DCs and further up-regulation of MHC-class II molecules, co-
stimulatory molecules, and cytokine production in DCs. Both,
preclinical trials in a melanoma model (Dranoff et al., 1993)
and a clinical studies in melanoma patients have shown the
potential of autologous GVAX cells to elicit a tumor specific long-
lasting anti-tumor response (Hege et al., 2006). GVAX was tested
in numerous tumor entities with autologous tumor cell lines
including renal (Tani et al., 2004), melanoma (Kusumoto et al.,
2001; Soiffer et al., 2003), and non-small lung carcinoma (Salgia
et al., 2003). Finally, GVAX therapies were designed for allogeneic
settings in pancreatic and prostate cancer (Copier et al., 2007).
“Prostate-GVAX” is the most advanced approach and two ran-
domized phase III studies have been running (Higano et al., 2009;
Small et al., 2009). The vaccine consists of two prostate cancer
cell lines that were genetically modified by adenoviral transfec-
tion to produce GM-CSF. In one trial, GVAX was compared
with CT (docetaxel plus prednison), while the other one com-
prised GVAX plus CT as study arm, and CT alone as control
arm. Disappointingly, both studies were terminated prematurely,
because it has turned out that control arm was more beneficial
compared to the study arm regarding OS (Joniau et al., 2012).
There are further approaches using allogenic, genetically
modified whole tumor cells as tumor vaccine. The group of
Nemunaitis et al. tested the administration of the TGF-beta2
antisense gene modified allogeneic tumor cell compound in the
treatment of non-small lung carcinoma; promising results were
obtained in a phase II trial (Nemunaitis et al., 2006). The admin-
istration of the vaccine resulted in partial response rates of 15%,
but failed in initiating a significant improvement in the overall
response rate in the vaccine group. It was therefore not pursued
in clinical trials (Nemunaitis et al., 2006). Contrary, canvaxin, as
an example for a whole cell tumor vaccine consisting of unmod-
ified allogeneic tumor cells, made its way into clinical trials.
Canvaxin is composed of irradiation inactivated three different
cell lines that express various TAs for melanoma. Administrated
with BCG as an adjuvant resulted in immunological responses
detected by DTH response and IgM level in the sera of the
patients. This response correlated with increased median survival
(Morton et al., 1992). The canvaxin phase II studies were promis-
ing and had proven survival benefits for stage III melanoma
patients and even complete remissions in patients with low vol-
ume disease (after surgical removal) (Hsueh et al., 1999; Morton
et al., 2002). Nevertheless, this approach failed in a phase III study,
which was terminated earlier because the efficiency of control arm
(BCG+ placebo) was stronger, compared to the study arm (Finke
et al., 2007). To conclude, many of the allogeneic-based vaccine
approaches failed in the end in clinical trials. Therefore, autolo-
gous tumor cell based vaccines will be more in the focus of future
vaccine developments (Fournier and Schirrmacher, 2009).
HIGH HYDROSTATIC PRESSURE AS PROMISING VACCINE
PREPARATION METHOD
Although there are some promising approaches in the field of
whole cell-based vaccines, the clinical outcome still remains
unsatisfactory. One major problem could be the low immuno-
genicity of the vaccines and/or the failure of establishing an
immunological memory. The clinical success is mainly proven
in phase I and phase II trials. Dalgleish suggests that differences
in clinical centers may contribute to the disappointing outcome
in the phase III randomized studies and assumes that parameters
like diet, exercise, and supplements might determine anti-tumor
effect more than supposed (Dalgleish, 2011).
The production of the vaccines is another major challenge.
Long processing times and reproducibility are still major prob-
lems. Strategies are needed that allow both, simple processing of
tumor cells by concomitantly rendering them immunogenic. Cell
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death pathways and death stimuli are closely connected to the
tumor cell’s immunogenic potential. However, despite the numer-
ous vaccine approaches, hardly any work has taken into account
the immunogenicity of the tumor cells that is determined by the
different inactivation methods (Tesniere et al., 2008a).
Therefore, our group has focused on how a distinct inactiva-
tion method renders the dead tumor cells immunogenic (Weiss
et al., 2010a). We examine HHP as a novel and innovative inac-
tivation method for the generation of whole tumor cell-based
vaccines. Focus is set on inactivation efficiency and the potential
to deliver tumor cells with high immunogenicity. The HHP-
technology is a highly reproducible technology, since pressure
force vectors act orthogonal, with equal absolute value on the cell
surface. Further, pressure propagation is homogenous and quasi
not delayed (sound-velocitiy in media, see Figure 2A). Treatment
with HHP preserves the shape of the cells and induces a gel-like
consistence of cytoplasm (Frey et al., 2008). Importantly, exper-
iments with several tumor cell lines treated with pressure equal
or above 200MPa have already proven that tumor cells are totally
inactivated (Weiss et al., 2010b). So the pressurization of cells with
200MPa leads to a mixture of apoptotic and necrotic cells (Frey
et al., 2004; Korn et al., 2004; Weiss et al., 2010a). This mixture of
dead cells, the cell morphology, and the observed release of dan-
ger signals after HHP treatment suggest that the tumor cells have
a sufficient high enough immunogenic potential after inactiva-
tion with 200MPa of HHP. We have demonstrated that tumor
cells that were inactivated with 200MPa HHP release DAMPs
such as HMGB-1 andHsp70 (own unpublished data). We further
already revealed that the administration of HHP-treated autol-
ogous tumor cells without any adjuvant leads to a reduction of
tumor outgrowth as well as to an advantage in survival in CT26
colorectal tumor bearing Balb/c mice. This was observed in a pro-
phylactic setting (Weiss et al., 2010b). Taken together, the main
prerequisites (summarized in Figure 2B) for a whole cell-based
tumor vaccine are fulfilled by the application of HHP.
RADIOTHERAPY COMBINED WITH IMMUNOTHERAPY FOR
INDUCTION OF ANTI-TUMOR RESPONSES
Immunotherapy provided as mono-therapy won’t be success-
ful in destroying huger tumor masses. However in combination
with standard therapies that reduce the tumor burden, it can
be an effective tool to obtain a prolonged anti-tumor effect.
Immune surveillance diminishes the risk for the development
of metastases and tumor recurrence. The combination of RT
with immunotherapy therefore offers great prospects to induce
a strong and prolonged anti-tumor effect.
RT is, besides CT and surgery, one of the well-established
methods in clinical cancer treatment. The primary effect of RT
relies on the local killing of tumor cells by damaging the DNA.
However, there is growing evidence that the impact of RT is not
restricted to the local destruction of tumor cells, but also on the
modification of the tumor’s microenvironment. It may induce
abscopal effects and positively influence the systemic therapeutic
outcome (Frey et al., 2012).
Solid tumors are characterized by an atypical vascular
network. Additionally, tumor-associated macrophages (TAM),
myeloid-derived suppressor cells (MDSC) (Marigo et al., 2008),
FIGURE 2 | High hydrostatic pressure (HHP) Technology as an
innovative method for the preparation of whole tumor cell-based
vaccines. The basic principle of the HHP technology is displayed in (A). The
tumor cell suspension, which has to be pressurized, has to be packed in a
plastic wrapping. The pressure is applied to the treatment cavity and
propagates through the pressure transmitting medium and also through the
packaging (Yaldagard et al., 2008). Since the pressure is a vector product its
acts on every material in the cavity with the same amplitude, independent
of the shape of the probe. It was obvious in different experiments, that the
pressure for inactivation should be at least equal or above 200MPa. For the
production of an effective whole cell-based vaccine, four main requirements
have to be fulfilled (B): the vaccine has to be safe, i.e., it has to exhibit low
toxicity and, especially in the case of autologous tumor cell-based vaccines,
the tumor cell material has to be effectively inactivated. The vaccine has to
be further highly immunogenic, i.e., it has to trigger the immune system to
elicit a strong anti-tumor response accompanied by the development of an
immunological memory against the tumor. Finally, the vaccine and its
processing have to be in accordance with statutory provisions.
and regulatory T-cells may foster tumor progression. They secrete
chemo- and cytokines such as VEGF, IL-10, and TGF-β to sup-
press the maturation of DCs. They therefore hamper APCs to
establish an immune response against the tumor (Melief, 2008).
Since irradiation modifies the tumor cell’s phenotype and the
tumor microenvironment, it may contribute via bystander effects
to tumor regression (Lorimore et al., 2001). It has turned out
that ionizing radiation can induce pro-inflammatory conditions
in the tumor by causing immunogenic cell death, associated
with the release of danger signals such HMGB-1. Further, an
increased macrophage activation and neutrophil infiltration has
been observed after RT (Lorimore et al., 2001). Antitumor effects
outside of the radiation field were already observed in numer-
ous studies (Ehlers and Fridman, 1973; Ohba et al., 1998; Okuma
et al., 2011). Originally, this phenomenon (the so called abscopal
effects of X-ray) was described by Mole in 1953. Even though the
molecular mechanisms are not fully known, it has become evi-
dent that the immune system plays a significant role (Mole, 1953;
Demaria et al., 2004; Formenti and Demaria, 2009; Frey et al.,
2012).
Due to their immunogenic features induced by e.g., RT, the
dead tumor cells are rendered visible for immune surveillance.
This can be regarded as an “intrinsic vaccination.” Preclinical
experiments with tumor bearing mice that have been treated with
RT and CTLA-4 blocking agents revealed that CTLA-4 therapy
on its own is not able to elicit a systemic effect in regard to tumor
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outgrowth of a second, non-irradiated tumor. However, combi-
natory treatment with CTLA-4 blocking agents and fractionated
RT resulted in a significant growth retardation of the tumor out-
side the radiation field (Dewan et al., 2009). Furthermore, it was
observed by Schaue et al. that irradiation resulted in a dose-
dependent increase of IFNγ producing T-cells that correlated with
tumor control (Schaue et al., 2012).
The pivotal role of DCs for radiation-induced abscopal
immune effects was demonstrated by Demaria et al. (2004).
Ionizing irradiation further directly influences the ability of DCs
to load antigens being associated with an improved cross-priming
of T-cells (Teitz-Tennenbaum et al., 2008). Knowing that irradi-
ation may elicit immunological responses directed against tumor
cells when combined with further immune activation, the appli-
cation of an additional immunotherapy to RT might be a promis-
ing approach in tumor therapy (Demaria et al., 2005). Auspicious
preclinical trials examining RT in combination with cytokines
(especially IL-3 and IL-12) and DC applications, have already
been performed (Maraskovsky et al., 1996; Chiang et al., 1997;
Lynch et al., 1997; Seetharam et al., 1999; Teitz-Tennenbaum
et al., 2003; Trinchieri, 2003; Oh et al., 2004). In a rat model
of glioma, the combination of a vaccine composed of irradiated
glioma cells and RT was tested. Despite vaccination alone results
in a reduced survival compared to the control group, the combi-
nation of RT with the vaccine was superior in regard to survival
than RT alone (Graf et al., 2002). Using a mouse model of glioma,
the combination of a vaccine consisting of cytokine-producing
autologous cancer cell with RT was tested. This combination
resulted in cure of mice; unfortunately, a group just receiving RT
alone was not included in this study (Lumniczky et al., 2002).
To summarize, some combination therapies of RT and
immunotherapy have already reached the level of clinical studies.
As one further example, in a phase II trial for prostate cancer,
the combination of standard RT and vaccination with poxvirus
encoding prostate-specific antigen was examined in a two arm
setting (combination versus RT only). The combination therapy
provoked a cellular immune response with T-lymphocytes that
were not only restricted to the TAs provided by the vaccine. This
implies a radiation-induced in vivo immunization effect (Gulley
et al., 2005).
OUTLOOK
The outcomes of multimodal cancer therapies including
immunotherapy are complex. While treatments with antibodies
are already established in the daily clinical routine, the treatment
of cancer with whole cell-based vaccines is still at an experimental
stage. However, recent studies revealed that such immunother-
apeutic agents may broaden the anti-tumor response in cancer
patients (Mellman et al., 2011). CI can help to overcome the
immune suppression emanating from the tumor. Nowadays, it
has become clear that the standard tumor therapies elicit local
and abscopal effects (summarized in Frey et al., 2012) that could
be potentiated when combined with cancer vaccines (Sistigu et al.,
2011). Future research is needed focusing on which combination
of standard therapies (surgery, RT, CT, RCT) with CI are most
beneficial and in which tumor stage and chronology they should
be applied.
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